72 results about "Artificial pancreas" patented technology

A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and / or a detected location of the user.

Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg / dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg / dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.

The application discloses a closed-loop artificial pancreas insulin infusion control system, which comprises a detection module, a program module and an infusion module.The detection module is used for continuously detecting a current blood glucose value G.The program module is connected with the detection module, and a mixed artificial pancreas algorithm is preset in the program module, which is used for calculating an insulin infusion amount required by a user.The mixed artificial pancreas algorithm comprises a cPID algorithm and / or a cMPC algorithm.The input of the cPID algorithm is an intermediate value of the MPC algorithm, and the input of the cMPC algorithm is an output value of the PID algorithm.The infusion module is connected with the program module, and the program module sends the insulin infusion amount to the infusion module, and the infusion module infuses insulin according to the insulin infusion amount.Through deep combination of the PID algorithm and the MPC algorithm, the advantages of the PID algorithm and the MPC algorithm are fully utilized, the infusion result is more accurate and reliable, and the precise control of the closed-loop artificial pancreas insulin infusion system is realized.

A method for controlling glucose in a flexibly configured dual-hormone artificial pancreas, which manages optional meal and / or exercise notifications using coordinated control actions, comprising the steps of: measuring a plasma glucose signal; calculating the increase (y) of the plasma glucose measurement; defining a model for the increase in plasma glucose; defining carbohydrate intake depending on the carbohydrate content estimated by the patient; and calculating the expected postprandial increase (y) of plasma glucose depending on the administered insulin bolus. * (s) step of defining the increase in corrected plasma glucose TIFF2026529166000143.tif69, corrected insulin infusion volume TIFF2026529166000144.tif59, and adjusted carbohydrate intake Steps to define TIFF2026529166000145.tif69; control action μ r and antagonistic control action μ cr The steps include defining a virtual control action μ(s) divided into and and a nominal value prefilter F r A method comprising the step of calculating a control action using a two-degree-of-freedom (2-DOF) feedback controller having (s).

The invention discloses an automatic detection method based on the change rate of the difference between the actual blood glucose values, including: obtaining an actual blood glucose value of the user at the current time; obtaining a historical actual blood glucose value of the user at the previous time, and calculate a difference between the actual blood glucose values at the current time and at the previous time; calculating a change rate of the difference between the actual blood glucose values at the current time; and comparing the change rate of the difference between the actual blood glucose values at the current time with a preset threshold, and determining an event type based on the comparing result. Based on the determined event type, the artificial pancreas can automatically adjust the corresponding infusion strategy to achieve closed-loop control of the artificial pancreas.

The invention relates to a device for distributing and receiving a population of pancreatic islets heterogeneous in size, the device comprising a matrix having a first face opposite a second face, characterized in that the matrix comprises concentric channels centered on a center O, the channels have an opening for receiving the pancreatic cells, the opening leading out onto the first face, the opening extending over the entire length (L) of the channel, the opening having a width (I) taken along the section Si, the device being configured such that the widths of the opening of two adjacent channels have an equal or increasing value moving away from the center O and such that the widths of the opening of a channel closest to the center O and of a channel furthest from the center O have an increasing value moving away from the center O. The invention relates to the field of implantable devices, in particular artificial pancreas devices.

The invention discloses a closed-loop artificial pancreas device with integrated detection and infusion, comprising: infusion unit configured to deliver drugs; program unit comprising input end and output end, and the input end comprises a plurality of electrically connective regions for receiving signals of analyte data in the body fluid, after the output end is electrically connected to the infusion unit, according to the received signals of analyte data in the body fluid, the program unit controls whether the infusion unit delivers drugs; an infusion cannula with conductive area, the infusion cannula is the drug infusion channel; and a plurality of electrodes for detecting analyte data in body fluid, the electrode comprising conductive-area electrode and cannula-wall electrode, the conductive area of the infusion cannula being at least as a conductive-area electrode, and one or more cannula-wall electrodes being located on / in the wall of the infusion cannula.

This invention provides a system and method to protect an artificial pancreas' sensor, infusion system, and alert systems from EMI / wireless attacks using a medical software or application, close the gap between sensor glucose and blood glucose, and build a non-invasive hypoglycemia and hyperglycemia false alarm detection scheme with the help of a wristband. This inventive method and system provides a more accurate blood glucose prediction. It comprises preprocessing the CGM readings with Kalman smoothing for sensor error correction improves the robustness of the BG prediction. In one or more embodiments, the inventive system and method uses one or more physiological information such as meal, insulin, aggregations of step count, and preprocessed CGM data. The invention provides a novel approach for leveraging the stacked LSTM based deep RNN model to improve the BG prediction accuracy. The invention provides a special circuits-Transduction Shield-to detect and correct the sensor errors caused by EMI attacks.

Adaptive body load estimation of exogenous drugs responsive to transient (i.e., transient) physiological effects is provided. Dynamic estimation of an equivalent amount of a body-borne exogenous drug (XOB), such as insulin and / or carbohydrate, remaining in a subject is made based on prediction of glucose time series data. These estimates, such as insulin-on-body (IOB), may be used in diabetes management software, e.g., including decision support and / or artificial pancreas (AP) algorithms.

The application discloses a personalized closed-loop artificial pancreas system, which comprises a detection module (100) for continuously detecting blood glucose values of a patient, an infusion module (102) for infusing insulin into the patient, and a program module (101) for controlling the detection module (100) and the infusion module (102). The program module (101) generates insulin infusion instructions according to the blood glucose values detected by the detection module (100) and controls the infusion module (102) to perform infusion. The program module (101) comprises a user interface. In response to an input of the patient, the program module (101) executes a corresponding meal mode function. The meal mode comprises a high-carbohydrate mode and a normal-carbohydrate meal mode. According to the input of the patient, the program module (101) executes the function of the high-carbohydrate mode or the normal-carbohydrate mode, so as to be applicable to people with different carbohydrate consumption habits, improve the adaptability of the closed-loop artificial pancreas to different people, and enable people with different carbohydrate consumption habits to maintain a satisfactory blood glucose control effect.

A personalized closed-loop infusion system and method. Relevant information of patients is uploaded to a cloud server (104), and is grouped on the basis of identifiable features of the patients; the relevant information of different patients, such as blood glucose data records and insulin infusion data records, is compared in a same group; and when the relevant information of the patients is the same or similar, insulin algorithm parameters of patients with well-controlled blood glucose can be used for modifying an insulin algorithm of patients with poorly-controlled blood glucose, and a closed-loop artificial pancreas system can quickly obtain personalized insulin algorithms suitable for the patients without the need of long-period learning of physiological characteristics and lifestyle habits of the patients, thereby benefiting diabetes treatment of the patients.

Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

The application discloses a closed-loop artificial pancreas medicine infusion control system, which comprises an infusion module for outputting medicine, a program module, an input end and an output end of the program module, a plurality of electric connection areas of the input end for receiving a current blood glucose value, an algorithm preset in the program module, the output end and the infusion module being electrically connected, the algorithm calculating a required medicine amount of a user according to the received current blood glucose value, the program module controlling the infusion module to output the medicine according to the calculated required medicine amount of the user, and an infusion hose provided with at least two detection electrodes, the infusion hose being a medicine infusion channel, the electrodes being arranged on a pipe wall of the infusion hose, the infusion hose being communicated with the infusion module when the infusion hose is installed to a working position, the medicine flowing to the body through the infusion hose, and the different electrodes being electrically connected with different electric connection areas respectively to input the current blood glucose value into the program module. The algorithm is used to realize accurate control of the closed-loop artificial pancreas medicine infusion system.

This invention discloses a closed-loop infusion system and method based on food image recognition. An imaging module acquires food images, and a food image recognition model analyzes these images to obtain food data. An insulin algorithm determines the patient's postprandial insulin infusion volume based on the food data and simulates the patient's postprandial blood glucose. While the artificial pancreas infuses insulin, real-time blood glucose data is monitored. The real-time blood glucose data is compared with the simulated blood glucose data, and the comparison results are used to correct the parameters of the insulin algorithm, making it more suitable for patients. This improves the accuracy and adaptability of the insulin algorithm and benefits the treatment of diabetes.

An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg / dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg / dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.

The invention discloses a miniature closed-loop artificial pancreas system, comprising: infusion unit configured to deliver drugs; program unit comprising input end and output end, and the input end comprises a plurality of electrically connective regions for receiving signals of analyte data in the body fluid, after the output end is electrically connected to the infusion unit, according to the received signals of analyte data in the body fluid, the program unit controls whether the infusion unit delivers drugs; an infusion cannula with conductive area, the infusion cannula is the drug infusion channel; and a plurality of electrodes for detecting analyte data in body fluid, the electrode comprising conductive-area electrode and cannula-wall electrode, and one or more cannula-wall electrodes being located on / in the wall of the infusion cannula. It takes only one insertion to perform both analyte detection and drug infusion.

The application discloses a full-closed-loop artificial pancreas medicine infusion control system, which comprises a program module, at least one detection module, a hypoglycemic medicine infusion module and a hyperglycemic medicine infusion module. An algorithm is preset in the program module, the detection module detects blood glucose values, the hypoglycemic medicine infusion module performs hypoglycemic medicine infusion according to infusion instructions calculated by the algorithm, the hyperglycemic medicine infusion module performs hyperglycemic medicine infusion according to infusion instructions calculated by the algorithm, and full-closed-loop control of artificial pancreas system medicine infusion is realized.

The application discloses a closed-loop artificial pancreas insulin infusion control system, which comprises a detection module, an infusion module, a program module and an electronic module.The detection module is used for continuously detecting the current blood glucose value in a user's body; the infusion module comprises an infusion processor, a second processor and a program module; the infusion processor is used for calculating a first insulin infusion amount I1 according to the current blood glucose value by a first algorithm; the second processor is used for calculating a second insulin infusion amount I2 according to the current blood glucose value by a second algorithm; the program module is connected with the detection module and used for controlling the detection module and the infusion module; and the electronic module is used for optimizing and calculating the first insulin infusion amount I1 and the second insulin infusion amount I2 by a third algorithm to obtain a final insulin infusion amount I3, and sending the final insulin infusion amount I3 to the infusion module, so that the infusion module performs insulin infusion according to the final infusion amount I3.Through further processing of the result, the infusion result is more accurate and reliable, and the precise control of the closed-loop artificial pancreas insulin infusion system is realized.

The invention discloses a closed-loop artificial pancreas system which comprises a detection module used for continuously detecting the blood glucose level of a patient; the infusion module is used for infusing insulin into the body of the patient; the program module is used for controlling the detection module and the infusion module, at least according to the blood glucose value detected by the detection module, the program module generates an insulin infusion instruction and controls the infusion module to conduct infusion, the system adopts an infusion strategy of pre-infusion and supplementary infusion, the pre-infusion insulin amount is related to the pre-infusion meal amount, and the supplementary infusion amount is related to the pre-infusion meal amount. The supplementary infusion insulin amount is related to the meal amount estimated during supplementary infusion, the meal amount does not need to be determined clearly, the system determines the to-be-infused insulin amount according to the estimated meal amount, on one hand, the pressure for accurately determining the meal amount is relieved, and on the other hand, the meal amount can be accurately determined; meanwhile, the dynamic influence on the blood glucose level after dining and infusion of a large dosage is considered, and the infusion strategy of pre-infusion and supplementary infusion is adopted, so that the blood glucose level of a patient is kept at an ideal level.

An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg / dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg / dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.

Examples of a simulation framework are provided to evaluate time varying systems using a piecewise linear time invariant simulation (PLIS) approach. The simulation framework can be configured for an artificial pancreas wireless network system that controls blood glucose in Type 1 Diabetes patients with time varying properties such as physiological changes associated with psychological stress and meal patterns.

The present invention discloses an integrated wireless control patch for blood glucose sensing and regulation similar to an artificial pancreas and its preparation method, belonging to the field of biomedical engineering. The present invention realizes the integration of blood glucose sensing and regulation, integrates a color sensor and an ultraviolet cut-off filter, and monitors blood glucose in real time in situ, facilitating the timely acquisition of blood glucose information; then, a heater controls the release of metformin by temperature-responsive therapeutic microneedles to regulate blood glucose levels; the present invention uses near-field communication technology for wireless power supply regulation and communication. It gets rid of the limitations of power supplies and batteries, reduces the volume and weight of the patch, and improves the wearing comfort of patients. The present invention integrates monitoring and treatment functions to form a closed-loop system similar to an artificial pancreas. When a high blood glucose level is detected, the heater is automatically turned on for metformin drug delivery to reduce the blood glucose level, ensuring precise and timely blood glucose regulation. When the blood glucose level is low, the heater is not turned on, reducing the risk of hypoglycemia.

The application discloses a closed-loop artificial pancreas medicine infusion control system, which comprises an infusion module for outputting medicine, a program module, an input end and an output end of the program module, a plurality of electric connection areas of the input end for receiving a current blood glucose value, an algorithm of the program module for calculating a required medicine amount of a user, the output end and the infusion module being electrically connected, the program module controlling the infusion module to output medicine according to the calculated required medicine amount of the user, and an infusion hose provided with at least two detection electrodes, the infusion hose being a medicine infusion channel, the electrodes being arranged on a pipe wall of the infusion hose, the infusion hose being communicated with the infusion module when the infusion hose is installed to a working position, medicine flowing to a body through the infusion hose, and the different electrodes being electrically connected with different electric connection areas respectively to input the current blood glucose value into the program module. The algorithm is used to realize accurate control of the closed-loop artificial pancreas medicine infusion system.

An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg / dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg / dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.

The application discloses a closed-loop artificial pancreas medicine infusion control system, which comprises an infusion module for outputting medicine, a program module comprising an input end and an output end, the input end comprising a plurality of electric connection areas for receiving a current blood glucose value, the program module being further provided with an algorithm, the output end being electrically connected with the infusion module, the algorithm being used for calculating a required medicine amount of a user according to the received current blood glucose value, and the program module being used for controlling the infusion module to output the medicine; an infusion tube with a conductive area, the infusion tube being a medicine infusion channel; and a plurality of electrodes for detecting blood glucose, the conductive area of the infusion tube serving as at least one conductive area electrode, when the infusion tube is installed to a working position, the infusion tube is communicated with the infusion module, so that the medicine flows to the body through the infusion tube, and different electrodes are electrically connected with different electric connection areas to input the current blood glucose value into the program module. The algorithm is used for realizing accurate control of the closed-loop artificial pancreas medicine infusion system.

An integrated artificial pancreas with multiple infusion modes, includes: drug infusion unit; program unit comprising input end and output end, and the input end comprises a plurality of electrically connective regions for receiving signals of analyte data in the body fluid, after the output end is electrically connected to the power unit, the program unit controls whether the drug infusion unit delivers drugs; and an infusion cannula provided with at least two detecting electrodes, the infusion cannula is the drug infusion channel, the electrodes are disposed on the cannula wall. It takes only one insertion to perform both analyte detection and drug infusion.

The application discloses a closed-loop artificial pancreas insulin infusion control system, which comprises a detection module, a program module connected with the detection module, an rMPC algorithm and a target blood glucose value G pre-set in the program module, and an infusion module. B The rMPC algorithm converts blood glucose in an original physical space which is asymmetric into blood glucose in an approximate symmetric risk space, can retain the characteristics of considering the changing short-term effects of a classical MPC algorithm, consider the asymmetry of blood glucose distribution, has the advantages of precision and flexibility, and realizes precise control of the closed-loop artificial pancreas insulin infusion system.

This invention discloses a closed-loop artificial pancreas multi-drug infusion control system, comprising: a detection module for detecting the current blood glucose level; a program module connected to the detection module, pre-programmed with one or more of the following algorithms: rMPC, rPID, and a composite artificial pancreas algorithm; and an infusion module connected to the program module, capable of infusing blood glucose-regulating and / or blood glucose-lowering drugs. Based on the corresponding output indications calculated by the rMPC, rPID, or composite artificial pancreas algorithm, the program module controls the infusion module to infuse the corresponding drugs. This system fully utilizes the advantages of the rPID and rMPC algorithms to handle complex scenarios, enabling the artificial pancreas to reliably provide the types and dosages of drugs for blood glucose control under various conditions, thereby achieving ideal blood glucose control and realizing precise control of the closed-loop artificial pancreas multi-drug infusion system.

The present invention relates to a method of controlling glucose in a flexible structure dual hormone artificial pancreas, the method managing optional meal and / or exercise alerts by means of coordinated control behavior, the method comprising: measuring a plasma glucose signal; calculating an incremental plasma glucose measure (y); defining an incremental plasma glucose model; defining carbohydrate uptake as a carbohydrate content estimated depending on the patient; defining an expected postprandial incremental plasma glucose according to the administered insulin bolus; defining a corrected incremental plasma glucose, a corrected insulin infusion, and a corrected carbohydrate uptake; defining a virtual control behavior, which is allocated between a regulatory behavior and an anti-regulatory behavior; and calculating the control behavior with a 2-DOF feedback controller having a pre-filter having a nominal value s).